Table 1.

Mean A1c reduction in clinical studies of GLP-1RA

Study	Duration (weeks)	Baseline A1c (%)	Treatment	Mean change in A1c (%)
Nauck et al21	26	8.4	LIRA 1.8 mg + MET	−1.0±0.1a
			LIRA 1.2 mg + MET	−1.0±0.1a
			LIRA 0.6 mg + MET	−0.7±0.1a
			Placebo + MET	+0.01±0.1
Vilsboll et al71	14	8.3	LIRA 1.9 mg	−1.45a
			LIRA 1.25 mg	−1.40a
			LIRA 0.65 mg	−0.98a
			Placebo	+0.29
Rosenstock et al23	16	8.0	ALBI 30 mg weekly	−0.87b
			ALBI 50 mg biweekly	−0.79b
			ALBI 100 mg monthly	−0.87b
			Placebo	−0.17
Grunberger et al20	12	7.7	DULA 1.5 mg weekly	−1.0±0.1a
			DULA 1.0 mg weekly	−1.0±0.1a
			DULA 0.5 mg weekly	−0.9±0.1a
			Placebo	0.0±0.1
Bolli et al25	24	8.0	LIXI one-step dose increase (10, 20 mg) + MET	−0.9±0.1c
			LIXI two-step dose increase (10, 15, 20 mg) + MET	−0.8±0.1c
			Placebo + MET	−0.4±0.1

Notes:

^aP<0.001 vs placebo;

^bP<0.003 vs placebo;

^cP<0.0001 vs placebo.

Abbreviations: ALBI, albiglutide; DULA, dulaglutide; EXEN, exenatide; GLP-1RA, glucagon-like peptide-1 receptor agonists; LIRA, liraglutide; LIXI, lixisenatide; MET, metformin.